A comparison of low-cost techniques for three-dimensional animal body measurement in livestock buildings

Data about health and development of animals are still now mostly collected through manual measurements or visual observations but these kinds of methods of collecting data are causes of several problems. Alternatively, optical sensing techniques can be implemented in order to overcome limitations arising from manual contact measurements. The present research discusses metrological analysis of Structure from motion (SfM) photogrammetry approach, low-cost LiDAR scanning and Microsoft Kinect v1 depth camera to three- dimensional animal body measurement, with specific reference to pigs. Analyses were carried out on fiberglass model to get rid of animal movements. Scans were captured based on a segmented approach, where different portion of the body have been imaged during different frames acquisition tasks. The obtained results demonstrate the high potential of 3D Kinect. LiDAR show a higher RMS value respect to Kinect and SfM most probably due to the collection approach based on single profiles rather than on surfaces. Anyway, the RMS of relative noise ranges between 0.7 and 4 mm, showing a high accuracy of reconstructions even for the others techniques

Il database per la progettazione integrata

Le informazioni ottenute dai dati sperimentali relativi alla progettazione e gestione delle attivit\ue0 di trasformazione di alimenti non sono strutturate e quindi non vengono utilizzate dai progettisti. Per questo il progetto di ricerca ha come finalit\ue0, oltre che eseguire sperimentazioni specifiche, i cui risultati sono presentati in altri lavori, anche quella di costruire una banca dati comune di riferimento

Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment

<p>Abstract</p> <p>Background</p> <p>Botulinum Toxin Type-A (BoNT/A) intraprostatic injection can induce prostatic involution and improve LUTS and urinary flow in patients with Benign Prostatic Enlargement (BPE). However, the duration of these effects is unknown. The objective of this work was to determine the duration of prostate volume reduction after one single intraprostatic injection of 200U of Botulinum Toxin Type-A.</p> <p>Methods</p> <p>This is an extension of a 6 month study in which 21 frail elderly patients with refractory urinary retention and unfit for surgery were submitted to intraprostatic injection of BoNT/A-200U, by ultrasound guided transrectal approach. In spite of frail conditions, eleven patients could be followed during 18 months. Prostate volume, total serum PSA, maximal flow rate (Qmax), residual volume (PVR) and IPSS-QoL scores were determined at 1, 3, 6, 12 and 18 months post-treatment.</p> <p>Results</p> <p>Mean prostate volume at baseline, 82 ± 16 ml progressively decreased from month one coming to 49 ± 9,5 ml (p = 0,003) at month six. From this moment on, prostate volume slowly recovered, becoming identical to baseline at 18 months (73 ± 16 ml, p = 0.03). Albeit non significant, serum PSA showed a 25% decrease from baseline to month 6. The 11 patients resumed spontaneous voiding at month one. Mean Qmax was 11,3 ± 1,7 ml/sec and remained unchanged during the follow-up period. PVR ranged from 55 ± 17 to 82 ± 20 ml and IPSS score from10 to 12 points.</p> <p>Conclusion</p> <p>Intraprostatic BoNT/A injection is safe and can reduce prostate volume for a period of 18 months. During this time a marked symptomatic improvement can be maintained.</p

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with &gt;80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

Assessing performance and value-creation capabilities in Lean healthcare: insights from a case study

Lean thinking is increasingly being applied worldwide. Yet its actual impact is still a puzzle, particularly when a ‘ full-implementation approach ’— which entails the adoption of a strategic approach to Lean dissemination on policy deployment procedures — is used. Focusing on the healthcare sector, this paper presents and tests a comprehensive measurement framework for Lean interventions. The paper explains how Lean testing can help decision-makers to solve managerial issues related to Lean initiatives